Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: US Stocks To Open Cautiously Higher, Earnings In Focus

Wed, 23rd Jul 2014 11:49

LONDON (Alliance News) - US stocks are set to open cautiously higher Wednesday, boosted by the the lack of consensus among EU leaders to impose sector-wide sanctions on the Russian economy, but muted in trepidation of a raft of corporate earnings.

Currently, the DJIA, the S&P 500, and the Nasdaq Composite all look set to open about 0.1% higher.

Investors have had a mixed reaction to the big technology stock earnings released after the market close Tuesday. Apple shares are 0.5% lower in the pre-market despite beating earnings per share expectations as sales were slightly lighter than expected, while Microsoft shares are about 1.5% higher after it announced its own numbers.

The focus will remain on US earnings, particularly the biotechnology and social media stocks given Fed Chair Janet Yellen's recent comments that valuations in those particular sectors look "stretched." All eyes will be on Facebook the company reports after the US closing bell.

"While the Federal Reserve is perhaps not the best source of equity analysis the comments do highlight the importance of today’s earnings reports from Biogen, Gilead Sciences and Facebook in justifying overall stock market valuations," said CMC Markets market analyst Jasper Lawler.

Pepsico has done what its soft drink rival Coca-Cola failed to do on Tuesday and impressed the market with its second quarter results, announcing earnings per share of USD1.32, ahead of the consensus expectation of USD1.23. Pepsico shares are moving higher in the premarket.

Amid a heightened focus on the airline after it decided to cancel all flights to Tel-Aviv on Tuesday due to a rocket exploding near the airport, Delta Airlines has reported second quarter earnings per share of USD0.94, up from USD0.8 a year earlier.

The US followed Delta's decision with a short-term ban on all flights to Tel-Aviv's Ben Gurion airport, although that didn't stop Secretary of State John Kerry landing there earlier Wednesday to attempt to advance ceasefire talks as the death toll from the conflict nears 650. The longer a flight ban to Tel-Aviv lasts, the greater the pressure on the US to broker a solution, both from the perspective of the economic effect on Israel, and frustrated US-Israelis and influential American Jews. Former New York Mayor Michael Bloombeg issued a statement Wednesday saying, "the flight restrictions are a mistake that hand Hamas an undeserved victory and should be lifted immediately."

US MBS mortgage applications jumped 2.4% in the week ended July 18, after falling 3.6% in the previous week. The only other release of note in the data calendar Wednesday is the eurozone consumer confidence index at 1500 BST, which is expected to remain unchanged in July at negative 7.5.

Ahead of the US opening bell, UK stocks are continuing to trade modestly higher, with the FTSE 100 up 0.2% at 6,806.01, the FTSE 250 up 0.3% at 15,697.82, and the AIM All-share up 0.1% at 773.07.

GlaxoSmithKline has dropped to the bottom of the FTSE 100, down 2.9%, after reporting a drop in first-half pretax profit to GBP1.89 billion from GBP2.70 billion in the previous year. Group revenue was also down to GBP11.17 billion from GBP13.1 billion. Glaxo said that full-year core earnings per share is now expected to be broadly similar to 2013.

Bank of England Governor Mark Carney has been speaking at a business conference in Glasgow ahead of the opening of the Commonwealth Games there, and following the release of the the latest BoE meeting minutes earlier Wednesday. After beginning with a games pun about the UK economy being the current holder of "fastest growing advanced economy in the world title," Carney went on to put the quarterly inflation report, due next month, squarely in focus for central bank watchers.

The BoE chief reiterated his recent message that real wage growth is now the key indicator as to when rates will rise, and that currently there are conflicting messages in the labour market, namely that unemployment is rapidly falling, but wage growth is stagnant.

"A key judgement for the MPC is when and to what extent these developments will translate into real wage growth, and in turn that wage growth into price pressures," Carney said. "Next month's Inflation Report provides the next opportunity to update our thinking on these important questions."

Carney also reiterated that the main risk to the UK economic recovery is an overheating of the housing market and the prospect of UK households indebtedness, which he used as one of the explanations for future rate rises being gradual.


By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.